Aurinia Pharmaceuticals Inc. Previous ETF Holding It
Aurinia Pharmaceuticals Inc. (AUPH). 10 retained portfolio positions. Missing dates and values remain unreported.
- AIIQ: Fund AI Powered International Equity ETF; Added / first observed 2020-08-31.
- AVDE: Fund Avantis International Equity ETF; Added / first observed 2021-08-31.
- AVUS: Fund Avantis U.S. Equity ETF; Added / first observed 2024-11-30.
- GGZ: Fund Gabelli Global Small & Mid Cap Value Trust; Added / first observed 2021-03-31.
Previous ETF Holding It
10 retained portfolio positions. Missing dates and values remain unreported.
| ETF | Fund | Added / first observed | Removed / first absent |
|---|---|---|---|
| AIIQ | AI Powered International Equity ETF | 2020-08-31 | |
| AVDE | Avantis International Equity ETF | 2021-08-31 | |
| AVUS | Avantis U.S. Equity ETF | 2024-11-30 | |
| GGZ | Gabelli Global Small & Mid Cap Value Trust | 2021-03-31 | |
| GRX | Gabelli Healthcare & WellnessRx Trust | 2021-03-31 | |
| LITL | Simplify Piper Sandler US Small-Cap PLUS Income ETF | 2025-12-31 | |
| NTKI | Nationwide Russell 2000 Risk-Managed Income ETF | 2022-08-31 | |
| ONEQ | Fidelity Nasdaq Composite Index ETF | 2015-08-31 | |
| REM | iShares Mortgage Real Estate ETF | 2018-06-30 | |
| SBIO | ALPS Medical Breakthroughs ETF | 2017-08-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |